Promising Biotech Stocks To Follow Today - November 17th

SELLAS Life Sciences Group logo with Healthcare background
Image from MarketBeat Media, LLC.

SELLAS Life Sciences Group, Moderna, Gilead Sciences, AbbVie, and Natera are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biotechnology to develop medicines, therapies, diagnostics, or other life-science products. For investors, they can offer growth potential but often carry higher risk and volatility because a company’s value may depend on uncertain research results, clinical trials, and regulatory approvals. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

SELLAS Life Sciences Group (SLS)

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

Shares of NASDAQ SLS traded up $12.08 during trading hours on Tuesday, reaching $19.55. 81,856,657 shares of the stock were exchanged, compared to its average volume of 8,194,631. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of -98.16 and a beta of 2.73. The stock's fifty day simple moving average is $10.90 and its 200 day simple moving average is $8.79. SELLAS Life Sciences Group has a 52 week low of $1.39 and a 52 week high of $24.89.

Read Our Latest Research Report on SLS

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

MRNA traded down $7.71 during trading on Tuesday, hitting $207.56. The stock had a trading volume of 3,278,564 shares, compared to its average volume of 12,506,583. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The company has a 50 day moving average price of $203.06 and a 200-day moving average price of $97.26. Moderna has a one year low of $22.28 and a one year high of $280.80. The firm has a market cap of $83.98 billion, a price-to-earnings ratio of -29.00 and a beta of 1.16.

Read Our Latest Research Report on MRNA

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

GILD stock traded up $2.09 during trading hours on Tuesday, hitting $169.67. 1,859,727 shares of the stock were exchanged, compared to its average volume of 6,767,535. Gilead Sciences has a 12 month low of $116.88 and a 12 month high of $176.58. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84. The firm has a market capitalization of $210.44 billion, a P/E ratio of -53.62 and a beta of 0.35. The company has a 50-day simple moving average of $155.43 and a two-hundred day simple moving average of $141.94.

Read Our Latest Research Report on GILD

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV stock traded down $1.82 on Tuesday, hitting $292.73. The company's stock had a trading volume of 960,251 shares, compared to its average volume of 6,270,341. AbbVie has a fifty-two week low of $190.75 and a fifty-two week high of $302.93. The company has a market capitalization of $517.43 billion, a PE ratio of 50.38, a PEG ratio of 1.34 and a beta of 0.20. The stock's 50 day moving average is $276.27 and its 200-day moving average is $241.28.

Read Our Latest Research Report on ABBV

Natera (NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Shares of NASDAQ NTRA traded down $9.00 during trading hours on Tuesday, hitting $279.48. 877,467 shares of the stock were exchanged, compared to its average volume of 1,469,046. Natera has a 1-year low of $181.00 and a 1-year high of $437.41. The company has a market cap of $40.53 billion, a PE ratio of -243.72 and a beta of 1.55. The company's fifty day simple moving average is $378.90 and its two-hundred day simple moving average is $271.87.

Read Our Latest Research Report on NTRA

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SELLAS Life Sciences Group Right Now?

Before you consider SELLAS Life Sciences Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.

While SELLAS Life Sciences Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines